1. WHO. Obsessive-compulsive disorder (OCD) [Internet]. WHO; [cited 2025 Jan 25]. Available from: https://applications.emro.who.int/docs/ WHOEMMNH232E-eng.pdf

2. Ferreira S, Couto B, Sousa M, Vieira R, Sousa N, Picó-Pérez M, Morgado P. Stress Influences the Effect of Obsessive-Compulsive Symptoms on Emotion Regulation. Front Psychiatry. 2021 Jan 20; 11: 594541. DOI:10.3389/fpsyt.2020.594541

3. Orozco A, Cardoner N, Aragón CF, Ruiz-Murugarren S, Vicens M, Álvarez-Mon MÁ, Lahera G. Obsessive–compulsive symptoms in anxiety and depressive disorders: Influence of recent and/or traumatic life events. Rev Psiquiatr Salud Ment (Engl Ed). 2021 Oct; 14(4):218-26. DOI: 10.1016/j.rpsmen.2020.12.002

4. Fenlon EE, Pinciotti CM, Jones AC, Rippey CS, Wild H, Hubert TJ, Tipsword JM, Badour CL, Adams TG. Assessment of Comorbid Obsessive-Compulsive Disorder and Posttraumatic Stress Disorder. Assessment. 2023 Oct 30. DOI: 10.1177/10731911231208403

5. Pro vvedennia voiennoho stanu v Ukraini, Ukaz Prezydenta Ukrainy № 64/2022 [Internet], 24 liut. 2022 [tsytovano 27 sich. 2025] (Ukraina). Available from: https://zakon.rada.gov.ua/laws/ show/64/2022#Text

6. WHO. Ukraine emergency [Internet]. WHO; 2023 [cited Jan 25 2025] Available from: https://www.who.int/emergencies/situations/ ukraine-emergency

7. Otroshchenko P, Otroshchenko N, Otroshchenko I. Depression in cancer patients during the COVID-19 pandemic. Ukrainian Scientific Medical Youth Journal.2021 Sep 30; 125(3): 23– 31. DOI: 10.32345/ USMYJ.3 (125).2021.23-31

8. Otroshchenko NP. Cognitive aspects of depression in victsms of radiation accidents, the covid-19 pandemic, and wars. Problemy radiatsiinoi medytsyny ta radiobiolohii = Problems of Radiation Medicine and Radiobiology. 2023 Jan 1; 28: 75–92. DOI: 10.33145/2304-8336- 2023-28-75-92

9. Howes OD, Thase ME, Pillinger T. Treatment resistance in psychiatry: state of the art and new directions. Molecular Psychiatry [Internet]. 2021 Jul 13; 27(1). DOI: 10.1038/s41380-021- 01200-3

10. Van Roessel PJ, Grassi G, Aboujaoude EN, Menchón JM, Van Ameringen M, Rodríguez CI. Treatment-resistant OCD: Pharmacotherapies in adults. Comprehensive Psychiatry. 2023 Jan 1; 120: 152352. DOI:10.1016/j. comppsych.2022.152352

11. Pro vnesennia zmin do deiakykh zakoniv Ukrainy shchodo derzhavnoho rehuliuvannia obihu roslyn rodu konopli (Cannabis) dlia vykorystannia u navchalnykh tsiliakh, osvitnii, naukovii ta naukovo-tekhnichnii diialnosti, vyrobnytstva narkotychnykh zasobiv, psykhotropnykh rechovyn ta likarskykh zasobiv z metoiu rozshyrennia dostupu patsiientiv do neobkhidnoho likuvannia, Zakon Ukrainy № 3528-IX [Internet], 21 hrud. 2023 [tsytovano 27 sich. 2025] (Ukraina). Dostupno na: https://zakon. rada.gov.ua/laws/show/3528-20#Text

12. Pro zatverdzhennia Pereliku form likarskykh zasobiv, yaki mozhut vyhotovliatys v umovakh apteky z roslynnoi substantsii kanabisu, Pereliku zakhvoriuvan ta staniv, za naiavnosti yakykh pryznachaiutsia likarski zasoby, yaki mozhut vyhotovliatysia v umovakh apteky z roslynnoi substantsii kanabisu, Osoblyvostei pryznachennia ta medychnoho zastosuvannia likarskykh zasobiv, yaki mozhut vyhotovliatysia v umovakh apteky z rosly, Nakaz Ministerstva okhorony zdorovia Ukrainy № 1586 [Internet], 13 veres. 2024 [tsytovano 27 sich. 2025] (Ukraina). Dostupno na: https://zakon.rada. gov.ua/laws/show/z1422-24#Text

13. Surkin PN, Gallino SL, Luce V, Correa F, Fernandez-Solari J, De Laurentiis A. Pharmacological augmentation of endocannabinoid signaling reduces the neuroendocrine response to stress. Psychoneuroendocrinology. 2018 Jan 1 [cited 2021 May 19]; 87:131–40. DOI:10.1016/j. psyneuen.2017.10.015 

14. Crocq MA. History of cannabis and the endocannabinoid system. Cannabinoids. Sep 2020; 22(3): 223-8. DOI:10.31887/dcns.2020.22.3/ mcrocq

15. Graczyk M, Łukowicz M, Dzierzanowski T. Prospects for the Use of Cannabinoids in Psychiatric Disorders. Front Psychiatry. 12 Mar 2021; 12. DOI: 10.3389/fpsyt.2021.620073

16. Cohen K, Weizman A, Weinstein A. Modulatory effects of cannabinoids on brain neurotransmission. Eur J Neurosci. 8 Apr 2019; 50(3): 2322-45. DOI: 10.1111/ejn.14407

17. Peters KZ, Cheer JF, Tonini R. Modulating the Neuromodulators: Dopamine, Serotonin, and the Endocannabinoid System. Trends in Neurosciences. 2021 Jun 1; 44(6): 464–77. DOI: 10.1016/j.tins.2021.02.001

18. Meccariello R, Santoro A, D'Angelo S, Morrone R, Fasano S, Viggiano A, Pierantoni R. Epigenetics of the endocannabinoid system. International Journal of Molecular Sciences. 2020; 21(3): 1113. DOI: 10.3390/ijms21031113

19. Fatima-Zahrae Laaboudi, Rejdali M, Amhamdi H, Amin Salhi, Abedellah Elyoussfi, M’hamed Ahari. In the weeds: A comprehensive review of cannabis; its chemical complexity, biosynthesis, and healing abilities. Toxicology Reports. 2024 Jun 29; 13: 101685–5. DOI:10.1016/j.toxrep.2024.101685

20. Dzierżanowski T. Prospects for the Use of Cannabinoids in Oncology and Palliative Care Practice: A Review of the Evidence. Cancers. 2019 Jan 22; 11(2):129. DOI: 10.3390/cancers11020129

21. Kayser RR, Snorrason I, Haney M, Lee FS, Simpson HB. The Endocannabinoid System: A New Treatment Target for Obsessive Compulsive Disorder? Cannabis and Cannabinoid Research. 2019 Jun; 4(2): 77–87. DOI:10.1089/ can.2018.0049

22. Rezende B, Alencar AKN, de Bem GF, Fontes-Dantas FL, Montes GC. Endocannabinoid System: Chemical Characteristics and Biological Activity. Pharmaceuticals. 2023 Jan 19; 16(2): 148. DOI: 10.3390/ph16020148 23. de Melo Reis RA, Isaac AR, Freitas HR, de Almeida MM, Schuck PF, Ferreira GC, et al. Quality of Life and a Surveillant Endocannabinoid System. Frontiers in Neuroscience. 2021 Oct 28; 15. DOI:10.3389/fnins.2021.747229

24. Inés Ibarra-Lecue, Diez-Alarcia R, Leyre Urigüen. Serotonin 2A receptors and cannabinoids. Progress in brain research. 2021 Jan 1; 135–75. DOI: 10.1016/bs.pbr.2021.01.004

25. Mohsen Hesami, Pepe M, Baiton A, Jones MP. Current status and future prospects in cannabinoid production through in vitro culture and synthetic biology. Biotechnology Advances. 2023 Jan 1; 62: 108074–4. DOI: 10.1016/j.biotechadv.2022.108074

26. Govindarajan RK, Mishra AK, Cho KH, Kim KH, Yoon KM, Baek KH. Biosynthesis of Phytocannabinoids and Structural Insights: A Review. Metabolites. 2023 Mar 17; 13(3): 442. DOI: 10.3390/metabo13030442

27. Dammann I, Rohleder C, F. Markus Leweke. Cannabidiol and its Potential Evidence-Based Psychiatric Benefits – A Critical Review. Pharmacopsychiatry. 2024 Jan 24; 57(03):115–32. DOI: 10.1055/a-2228-6118

28. Sultan W, Madiedo A, Moreno-Sanz G. Controlled inhalation of THC-predominant cannabis flos mitigates severity of PTSD symptoms and improves quality of sleep and general mood in cannabis-experienced UK civilians: a real-world, observational study. Medical Cannabis and Cannabinoids. 2024 Aug 28 [cited 2024 Nov 8]; 7(1): 149–59. DOI: 10.1159/000540978

29. Boylan PM, Santibañez M, Thomas J, Weeda E, Noel ZR, Caballero J. Cannabinoids for obstructive sleep apnea: A systematic review. Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy. 2024 Nov 1; 44(11): 880–91. DOI: 10.1002/phar.4622 30. Bonaccorso S, Ricciardi A, Zangani C, Chiappini S, Schifano F. Cannabidiol (CBD) use in psychiatric disorders: A systematic review. NeuroToxicology. 2019 Sep; 74:282–98. DOI:10.1016/j.neuro.2019.08.002

31. Hasbi A, Madras BK, George SR. Endocannabinoid System and Exogenous Cannabinoids in Depression and Anxiety: A Review. Brain Sciences. 2023 Feb 14; 13(2): 325. DOI: 10.3390/ brainsci13020325 

32. Prospéro-García O, Ruiz Contreras AE, Ortega Gómez A, Herrera-Solís A, Méndez-Díaz M. Endocannabinoids as Therapeutic Targets. Archives of Medical Research. 2019 Nov; 50(8):518–26. DOI:10.1016/j.arcmed.2019.09.005

33. Kashyap H, Abramovitch A. Neuropsychological Research in Obsessive-Compulsive Disorder: Current Status and Future Directions. Frontiers in Psychiatry. 2021 Nov 1; 12. DOI:10.3389/fpsyt.2021.721601

34. Mahjani B, Bey K, Boberg J, Burton C. Genetics of obsessive-compulsive disorder. Psychological Medicine. 2021 May 25; 51(13):1–13. DOI: 10.1017/S0033291721001744

35. Blanco-Vieira T, Radua J, Marcelino L, Bloch M, Mataix-Cols D, do Rosário MC. The genetic epidemiology of obsessive-compulsive disorder: a systematic review and meta-analysis. Translational Psychiatry. 2023 Jun 28; 13(1):230. DOI: 10.1038/s41398-023-02433-2

36. Bandelow B, Allgulander C, Baldwin DS, Costa DL da C, Denys D, Dilbaz N, et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for treatment of anxiety, obsessive-compulsive and posttraumatic stress disorders – Version 3. Part II: OCD and PTSD. The World Journal of Biological Psychiatry. 2022 Jul 28;1–17. DOI:10.1080/15622975.2022 .2086296

37. Welling MT, Deseo MA, Bacic A, Doblin MS. Biosynthetic origins of unusual cannabimimetic phytocannabinoids in Cannabis sativa L: A review. Phytochemistry. 2022 Sep; 201:113282. DOI:10.1016/j.phytochem.2022.113282

38. Boloc D, Mas S, Rodriguez N, Ortiz AE, Morer A, Plana MT, et al. Genetic Associations of Serotoninergic and GABAergic Genes in an Extended Collection of Early-Onset Obsessive-Compulsive Disorder Trios. Journal of Child and Adolescent Psychopharmacology. 2018 Oct 23; 29(2):152–7. DOI:10.1089/cap.2018.0073

39. Winter L, Heitland I, Saryyeva A, Lütjens G, Schwabe K, Heissler HE, et al. Acute Effects of Electrical Stimulation of the Bed Nucleus of the Stria Terminalis/Internal Capsule in Obsessive-Compulsive Disorder. World Neurosurgery. 2018 Mar; 111:e471–7. DOI.org/10.1016/j. wneu.2017.12.084

40. Bergfeld IO, Dijkstra E, Graat I, Pelle de Koning, van, Arbab T, et al. Invasive and Non-invasive Neurostimulation for OCD. Current topics in behavioral neurosciences. 2021 Jan 1; 399– 436. DOI: 10. 1007/7854_2020_206

41. Carmi L, Alyagon U, Barnea-Ygael N, Zohar J, Dar R, Zangen A. Clinical and electrophysiological outcomes of deep TMS over the medial prefrontal and anterior cingulate cortices in OCD patients. Brain Stimul. Jan 2018; 11(1):158-65. DOI: 10.1016/j.brs.2017.09.004

42. Szejko N, Fremer C, Müller-Vahl KR. Cannabis Improves Obsessive-Compulsive Disorder-Case Report and Review of the Literature. Frontiers in Psychiatry. 2020 Jul 21; 11. DOI: 10.3389/fpsyt.2020.00681

43. Yun JY, Boedhoe PSW, Vriend C, Jahanshad, N, Abe Y, Ameis SH, et al. Brain structural covariance networks in obsessive-compulsive disorder: a graph analysis from the ENIGMA Consortium [published correction appears in Brain. 2020 May 1;143(5):e44. DOI: 10.1093/ brain/awaa061]. Brain. 2020; 143(2): 684-700. DOI: 10.1093/brain/awaa001

44. Gargano SP, Santos MG, Taylor SM, Pastis I. A closer look to neural pathways and psychopharmacology of obsessive-compulsive disorder. Frontiers in Behavioral Neuroscience. 2023 Nov 16; 17. DOI: 10.3389/fnbeh.2023.1282246

45. Ahmari SE, Rauch SL.The prefrontal cortex and OCD. Neuropsychopharmacology. 2021 Aug 16; 47(1). DOI: 10.1038/s41386-021-01130-2

46. Delen E, Kucukali CI, Karaaslan Z, Yuceer H, Punar S, Hakan MT, et al. Investigation of the effects of oxidative stress, inflammation on the pathway of tryptophan/kynurenine in OCD. Acta Neuropsychiatrica. 2023 Nov 28; 1–11. DOI: 10.1017/neu.2023.55

47. Kayser RR, Raskin M, Snorrason I, Hezel DM, Haney M, Simpson HB. Cannabinoid augmentation of exposure-based psychotherapy for obsessive-compulsive disorder. J Clin Psychopharmacol. 2020; 40(2): 207-210. DOI: 10.1097/JCP.0000000000001179.

48. Anis S, Zalomek C, Korczyn AD, Rosenberg A, Giladi N, Gurevich T. Medical cannabis for Gilles de la Tourette syndrome: an open-la-bel prospective study. Behav Neurol. 2022; 2022:5141773. DOI: 10.1155/2022/5141773

49. Müller-Vahl KR, Pisarenko A, Szejko N, Haas M, Fremer C, Jakubovski E, Musil R, Münchau A, Neuner I, Huys D, Tebartz van Elst L, Schröder C, Ringlstetter R, Koch A, Jenz EB, Großhennig A. CANNA-TICS: Efficacy and safety of oral treatment with nabiximols in adults with chronic tic disorders – Results of a prospective, multicenter, randomized, double-blind, placebo-controlled, phase IIIb superiority study. Psychiatry Research. 2023; 323:115135. DOI: 10.1016/j.psychres.2023.115135

50. Müller-Vahl KR. Cannabinoids in the Treatment of Selected Mental Illnesses: Practical Approach and Overview of the Literature. Pharmacopsychiatry. 2024; 57(3):104-114. DOI: 10.1055/a-2256-0098